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Abstract: Recent meta-analyses highlight alterations in cognitive functioning among individuals
with major depressive disorder (MDD), with performance deficits observed across multiple cognitive
domains including executive functioning, memory, and attention. Moreover, impaired concentration
is a formal diagnostic criterion for a major depressive episode. Notably, cognitive impairment is
reported frequently in MDD and is associated with poor treatment response. Despite this knowledge,
research examining the effectiveness of top-down, adjunctive treatments for cognitive dysfunction in
MDD remains in its infancy. The primary aim of the present study was to perform a pilot investigation
of the implementation of a standardized cognitive remediation program, Goal Management Training
(GMT), among individuals with a primary diagnosis of MDD. A secondary aim was to explore how
comorbid symptoms of post-traumatic stress disorder (PTSD) among those MDD patients exposed to
trauma may affect treatment response. A final sample of thirty individuals were randomized to either
participate in the nine-week GMT program (active group; n = 16) or to complete a nine-week waiting
period (waitlist control; n = 14). One participant was excluded from the GMT group analysis following
study completion due to meeting an exclusion criteria. In total, 60% of the individuals allocated to
the GMT program were trauma exposed (n = 9). Groups were assessed at baseline, post-treatment,
and at three-month follow-up. The assessment comprised neuropsychological tasks assessing a
variety of cognitive domains, subjective measures of functioning and symptom severity, as well as a
clinical interview to establish a primary diagnosis of MDD. Significant gains in processing speed,
attention/concentration, and response inhibition were observed for the participants in the GMT
condition relative to participants in the waitlist control condition. Individuals in the GMT condition
also reported improvements in subjective cognitive functioning from baseline to post-treatment.
Heightened PTSD symptom severity was associated with reduced response to treatment with respect
to the domain of processing speed. The results of this pilot investigation highlight not only the
potential utility of GMT as an augmentative treatment in MDD, but also highlight the contribution of
comorbid symptoms of PTSD to diminished treatment response among trauma-exposed individuals
with MDD. The study is limited primarily by its small pilot sample and the absence of a program
evaluation component to gauge participant opinions and feedback of the treatment protocol.

creativecommons.org/licenses/by/
4.0/).
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1. Introduction
With a lifetime prevalence of 16.6% in North America [1], major depressive disorder
(MDD) is a common and chronic disorder characterized primarily by sustained periods
of low mood and a lack of interest in activities one normally enjoys [2]. In addition,
MDD is associated with a reduction in the ability to experience positive affect, such as
happiness or joy. Notably, MDD may develop following exposure to traumatic events and
is commonly comorbid with post-traumatic stress disorder (PTSD) [3–5]. For example,
30–50% of individuals with PTSD have also been found to meet diagnostic criteria for a
depressive disorder [3]. In addition to common affective and physical symptoms, both
disorders are associated with notable cognitive difficulties, with difficulty concentrating
among the formal symptoms described for each in the Diagnostic and Statistical Manual
for Mental Health Disorders-5-Text Revision (DSM-5-TR) [2]. Indeed, meta-analyses of
cognitive functioning in MDD point towards small to moderate effect sizes for deficits
across a range of cognitive domains, most notably in executive functioning (Cohen’s
d = −0.52 to −0.61) and attention (d = −0.22 to −0.54) [6]. Similarly, meta-analyses of
cognition in PTSD also reveal moderate effect size impairment across several cognitive
domains, including executive functioning (d = −0.45), verbal learning (d = −0.63) and
memory (d = −0.46), as well as visual learning (d = −0.27) and memory (d = −0.32) [7].
Critically, although there has been some debate about whether cognitive impairment is
a state or a trait characteristic in MDD, patients with MDD in full remission tend to exhibit
worse performance in cognitive domains, such as executive functioning and processing
speed relative to healthy controls; although this pattern of findings may be most strongly
associated with late-onset depression [8]. Moreover, as in depression, cognitive difficulties
in PTSD frequently persist following treatment (e.g., cognitive processing therapy and
prolonged exposure) [9]. Trauma exposure in MDD has further implications for patient
outcomes; heightened dissociative symptoms among trauma-exposed individuals with
MDD are associated with diminished processing speed and reductions in visuospatial recall
and verbal recognition [10].
Importantly, cognitive impairment among these neuropsychiatric conditions has been
associated with reduced functional outcomes [11,12], diminished response to pharmacological treatment [13], and attenuated response to behavioral treatment [14,15]. Despite these
well-documented deficits in cognitive function and their potential impact on functional and
treatment outcomes, research examining cognitive remediation approaches that directly
target cognitive function in MDD remains limited. The extant research, however, points
towards generally positive effects of cognitive remediation approaches in MDD. For example, a recent meta-analysis of interventions aimed at targeting cognitive performance in
MDD found moderate effects of computerized cognitive training on attention and working
memory, as well as improvements in symptom severity, daily functioning, and global
functioning [16].
Previous studies surrounding cognitive remediation in MDD have generally investigated bottom-up approaches (i.e., those targeting more basic cognitive abilities, such as
attention), as implemented in many computerized cognitive training protocols that rely
on drill and practice learning across limited cognitive domains, such as working memory
and attention (e.g., [17–19]). By contrast, only a limited number of studies have explored
top-down protocols aimed at introducing compensatory strategies for improving cognitive functioning among individuals with MDD, which often combine cognitive therapy
alongside a memory support intervention. For example, a novel memory support program
in addition to cognitive therapy for adults with MDD was associated with documented
improvements in recall of therapy sessions relative to those who received treatment as
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usual [20] (see also [21]). Additional research has also examined combining bottom-up and
top-down approaches, which also demonstrates some promise [22]. Specifically, therapistled, computerized, drill-based exercises in conjunction with metacognitive skills training
applied to daily living led to improvements in attention and verbal memory in individuals
with treatment-resistant depression in addition to functional improvement [22]. Thus,
although early work investigating top-down approaches to cognitive remediation in MDD
is promising, the relative dearth of studies in this area highlights an important gap in
the field.
Goal Management Training (GMT) is an established top-down cognitive remediation
program aimed at improving executive functioning via teaching participants a sequential
series of skills to monitor and improve goal-directed behaviors [23,24]. This program
utilizes a top-down approach by focusing on higher-order cognitive functions through the
introduction of psychoeducation, mindfulness, and other skills, such as goal setting and
self-monitoring, with the aim of improving supervisory control [23,24]. The program is
typically presented in a group format in order to foster group-specific benefits, such as
those seen in group cognitive behavioral therapy (CBT) [25], including sharing and normalization of experience, as well as accountability. GMT has been administered successfully
in a variety of clinical and non-clinical populations, such as those with acquired brain
injury, substance abuse, spina bifida, as well as older adults, where a recent meta-analysis
highlights consistent small-to-medium effects of improvements across a range of cognitive
domains, particularly executive function (Hedges’ g = 0.23 to 0.55) and long-term memory
(Hedges’ g = 0.27) [26].
GMT has also begun to be applied to other neuropsychiatric conditions, including
MDD. For example, Hagen et al. (2020) evaluated the effectiveness of GMT in a randomized controlled trial in MDD using the Norwegian-language adaptation of GMT [27]. At
six-month follow-up, GMT was associated with significant improvement on self-report
measures of executive functioning and depressive symptoms. GMT has also been associated with improvements in executive functioning, processing speed, verbal memory,
and symptom severity in individuals with PTSD [28,29], and in executive functioning and
subjective cognition in individuals with obsessive-compulsive disorder [30]. GMT may
also impact patterns of emotional response, improving performance on self-report and
objective measures of emotion regulation and impulsivity [28–30]. Notably, in these studies,
GMT appears to slow responding on challenging cognitive tasks, including when under
emotional distress (i.e., stopping to think before acting impulsively, a skill vital to emotion
regulation, including the management of anger and inappropriate comments and actions).
Due to the promising effects of this top-down approach in multiple populations, the
primary aim of the present study was to apply GMT in individuals with MDD. Specifically,
our primary aim was to examine the efficacy of GMT among an English-speaking sample of
individuals with MDD seeking treatment in a tertiary care setting (i.e., to determine whether
this protocol results in significant improvements in cognitive measures, such as executive
functioning, attention and memory, subjective cognition, and measures of psychological
well-being, such as symptom severity compared to a wait list control (WLC) group). We
hypothesized that, relative to the WLC group, participants in the GMT group would
should show greater improvements on outcome measures, particularly on measures of
executive function. A secondary aim of the study was to explore the influence of comorbid
PTSD symptom severity among trauma-exposed individuals with MDD, where PTSD
is further associated with cognitive impairment and may reduce response to treatment.
Accordingly, we explored the relation between severity of PTSD symptoms and response
to treatment (i.e., GMT) among a subset of trauma-exposed individuals with MDD in the
GMT group. We hypothesized a decreased response to treatment amongst individuals with
greater severity of PTSD symptoms. A final objective was to identify outcome measures
of interest using exploratory analyses for future large-scale investigations of GMT in
neuropsychiatric populations.
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2. Materials and Methods
2.1. Participants
Fifty-eight (n = 58) participants with a principal diagnosis of MDD according to DSMIV-TR or DSM-5 [2,31] were recruited from the outpatient Mood Disorders Program at
St. Joseph’s Healthcare Hamilton and invited to participate in this study. The inclusion
criteria were: (1) a principle diagnosis of major depressive disorder confirmed by the Mini
International Neuropsychiatric Interview 6.0 or 7.0 (M.I.N.I.) [32]; (2) between the ages of 18
and 65; and (3) able to provide written and informed consent. Participants were excluded
if they: (1) were receiving treatment with anti-cholinergic or anti-psychotic medication
known to adversely affect cognition; (2) had undergone ECT within the past year; (3) had a
history of substance dependence or significant and recent (<1 year) substance abuse; (4) had
a recent history (within the past 12 months) of a medical disorder known to adversely
affect cognition; (5) loss of consciousness greater than 1 min or a history of traumatic brain
injury; or (6) a learning disorder or other disorder known to adversely affect cognition such
as a diagnosis of attention-deficit/hyperactivity disorder (ADHD). Participants were not
required to discontinue or modify other treatments they were receiving concurrently for
MDD (e.g., antidepressant medication, psychotherapy). Twenty-nine (n = 29) individuals
dropped out or were excluded from the study between baseline (time 1) and post-treatment
testing (time 2). Eight (n = 8) individuals who were recruited to the study and randomized
were deemed to meet exclusion criteria during the first testing session. Within the GMT
group, eight individuals did not attend baseline testing after being screened or dropped
out prior to the first group GMT session, and one individual dropped out after the first
group GMT session. One GMT participant was excluded from analysis following group
completion due to use of anti-psychotic medication known to adversely affect cognition.
Within the WLC group, 11 individuals did not attend baseline testing or dropped out after
baseline testing. Thus, a final sample of twenty-nine (n = 29) individuals were included
in analysis following participation in the study, across both conditions. Among the final
sample within the GMT group, nine participants (n = 9) met criterion A for trauma exposure
on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) [33] and were included in
analyses of PTSD severity and response to treatment. See Figure 1 for a chart depicting
study recruitment, allocation, and loss to follow up.
2.2. Experimental Design and Procedure
Participants were assigned randomly (using https://www.sealedenvelope.com/simple-randomiser/v1/lists) to participate in either GMT or a 9-week waitlist control condition.
Participants were assessed at baseline, post-treatment, and 3-month follow-up. The experimental design is a 2 (group) × 3 (time) repeated-measures factorial design. Participants
randomized to the waitlist control condition were informed that they would have the
opportunity to participate in a therapist-led GMT group treatment at the end of the study.
Participants who had provided consent to be contacted regarding participation in
research studies upon referral to the Mood Disorders Outpatient Clinic were contacted
by trained study personnel (e.g., graduate and undergraduate students) to review the
study in detail and if interested, were invited to participate in the study. Participants were
also recruited via self-referral generated through advertisements on public forums (e.g.,
kijiji.ca and posters) or were referred to the study by their Mood Disorder Outpatient
clinicians (e.g., psychiatrists, nursing staff, and social workers). A detailed informed
consent form was reviewed and signed at the initial study appointment. At study entry,
participants completed a battery of self-report symptom and subjective cognition measures.
Participants also completed neuropsychological testing to assess executive functioning,
attention, and memory (see below), as well as several functional outcome measures. All
outcome measures were completed/administered at baseline (time 1), post-treatment
(time 2) and at 3-month follow-up (time 3). Participants completed a structured diagnostic
assessment, the M.I.N.I. 6.0 or 7.0 [32] and the CAPS-5 [33] at baseline. Trained researchers
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illustrate goal attainment failures and successes, as well as in-session practice on complex
recruited via self‐referral generated through advertisements on public forums (e.g., ki‐
tasks that mimic real-life tasks that are problematic for individuals with executive function
jiji.ca and posters) or were referred to the study by their Mood Disorder Outpatient clini‐
deficits (such as planning and attention).
cians (e.g., psychiatrists, nursing staff, and social workers). A detailed informed consent
In the present study, participants who attended at least one session of GMT, but
form was reviewed and signed at the initial study appointment. At study entry, partici‐
terminated treatment before completing the majority (55% or 5/9) of the GMT sessions,
pants completed a battery of self‐report symptom and subjective cognition measures. Par‐
were considered “drop-outs.” This value was determined by the expert opinion of clinicians
ticipants also completed neuropsychological testing to assess executive functioning, at‐
experienced with the GMT protocol and has been applied in previous investigations
tention, and memory (see below), as well as several functional outcome measures. All
(e.g., [30]). In the present study, one participant was counted as a dropout.
outcome measures were completed/administered at baseline (time 1), post‐treatment
(time 2) and at 3‐month follow‐up (time 3). Participants completed a structured diagnostic
assessment, the M.I.N.I. 6.0 or 7.0 [32] and the CAPS‐5 [33] at baseline. Trained researchers
at the graduate level or higher administered all study measures under the supervision of
a clinical psychologist.
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Table 1. Overview of Goal Management Training Protocol.
GMT Session

Description

Session 1: The Absent Mind, the Present Mind

Introduce the concept of absentmindedness and normalize the experience.
Explain present-mindedness using mindfulness techniques.

Session 2: Absentminded Slip-Ups

Introduce construct of absentminded slips with examples, and discuss emotional
and practical consequences. Introduce the “Body Scan” mindfulness exercise.

Session 3: The Automatic Pilot

Describe “automatic pilot” as being a habitual mechanism which can lead to
inappropriate responses or actions if not monitored. Introduce the “Breathing
Exercise” mindfulness technique.

Session 4: Stop the Automatic Pilot

Participants are introduced to the “STOP!” technique as a method of bringing
one’s attention to the present to monitor current behavior. The short “Breath
Focus” mindfulness exercise is described.

Session 5: The Mental Blackboard

The construct of working memory as a “mental blackboard,” which can be
erased or over saturated with information, is explained. Participants are taught
to check “the mental blackboard” to keep current goals at the forefront of
memory. Introduce how to incorporate present-mindedness (specifically the
“Breath Focus”) into behavior monitoring and executing difficult tasks as a
method for increasing accuracy and memory.

Session 6: State Your Goal

Describe how goals can become entangled when attempting to multi-task.
Introduce the concept of stating one’s goal as a way to aid encoding and recall of
that goal.

Session 7: Making Decisions

Introduce the concept of conflicting goals and detail strategies for how to make
decisions. Review methods for keeping track of complex goals using to-do lists.

Session 8: Splitting Tasks into Subtasks

Practice completing tasks that are too complex to rely on working memory only,
and detail strategies for how to divide large goals into a series of smaller, more
manageable subgoals.

Session 9: STOP!

Review the material covered across previous sessions and underscore the
importance of goal monitoring (the “STOP!” technique).

Table reproduced from [30].

2.3.2. WLC
Individuals randomized to this group were required to wait nine weeks, in addition
to a three-month follow-up period after which they were invited to commence GMT.
2.4. Measures and Materials
2.4.1. Clinical Interviews
MINI 6.0 or 7.0 [30]: The MINI is a brief, semi-structured, clinician administered
interview assessing psychiatric disorders including mood and anxiety disorders according
to the DSM-5 [2] and has high inter-rater reliability in psychiatric outpatients (κ > 0.75 for
all disorders) [30].
CAPS-5 [33]: The CAPS-5 is a semi-structured interview assessing PTSD diagnostic
criteria and symptom severity including frequency and intensity. The CAPS-5 has demonstrated high inter-rater reliability (κ = 0.78 to 1.00) and test-retest reliability (κ = 0.83), as
well as convergent validity (r = 0.66 to 0.83) and discriminant validity (r = 0.02 to 0.54) in
military veterans [33].
2.4.2. Symptom Measures
Beck Anxiety Inventory (BAI) [34]: The BAI is a 21-item, self-report questionnaire that
assesses anxiety symptoms over the past 30 days. The items consist of common symptoms
of anxiety, such as numbness, tingling, sweating and fearing the worst. The BAI has
demonstrated good internal consistency (α = 0.92 to 0.94), test-retest reliability (r = 0.67)
and validity in psychiatric outpatients [34,35].
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Beck Depression Inventory (BDI-II) [36]: The BDI-II is a 21-item, self-report questionnaire that assesses DSM-IV-TR defined symptoms of depression over the past 30 days.
Symptoms assessed include hopelessness and irritability, feelings of guilt or feelings of
being punished, as well as physical symptoms such as fatigue, weight loss, and lack of
interest in sex. The BDI-II has demonstrated high internal consistency (α = 0.92), test-retest
reliability (r = 0.93) and validity in psychiatric outpatients [37,38].
2.4.3. Subjective Cognition
Cognitive Failures Questionnaire (CFQ) [39]: The CFQ is a 25-item self-report questionnaire that captures daily errors in distractibility, blunders, names, and memory, and
has good test-retest reliability (α = 0.71) [40].
2.4.4. Neuropsychological Assessment
Attention and response inhibition were tested using the Conners’ Continuous Performance Test-II (CPT-II) [41] in which individuals maintain their focus to respond to
targets and inhibit response to non-targets. Processing speed was assessed using the Trail
Making Test Part A (TMT-A) [42] and the Wechsler Adult Intelligence Scale-IV (WAIS-IV)
Coding Subtest [43]. Processing speed and response inhibition were assessed using the
Trail Making Test Part B (TMT-B) [42] and the Stroop Color and Word Test [44] in which
color and word reading measured processing speed and the interference trial measured
response inhibition. The Wisconsin Card Sorting Task (WCST) [45] was used to assess
several executive function and related abilities, such as the ability to form and shift concepts. Finally, verbal memory was assessed using The California Verbal Learning Test-II
(CVLT-II) [46], a word list learning task which provides raw and z-scores for immediate
and delayed memory performance, interference learning and recognition. Normed scores
were used for all analyses.
2.5. Data Analysis
Only 8.7% of data points were missing, with more missing data tending to be found
among variables at the three-month follow-up appointment. The maximum number of data
points missing from any variable was 26.7%. The majority (55%) of variables had between
0–3.3% of data points missing. Missing data were handled with expectation–maximization.
Repeated measures 2 (Group) × 3 (Time) ANOVAs were used for all outcome variables with estimates of partial eta-squared for effect size (interpreted conservatively as
small = 0.01, medium = 0.10, and large = 0.25). Due to the exploratory pilot nature of this
investigation, with emphasis on effect size rather than on statistical significance alone, all
results were assessed with multivariate simple main effects regardless of significance of the
overall ANOVA given that it was expected that this sample would be underpowered to
reach significance in all cases. Multiple linear regression analyses were used for correlations
between baseline PTSD severity and change in outcome variables. We used an alpha level
of 0.05 for all statistical tests and all analyses were conducted using IBM SPSS version 26,
IBM Corp.
3. Results
The mean age of participants was 49.41 (SD = 10.46) and 25% were male. The average
level of education was 15.10 years (SD = 2.45) indicating completion of, at minimum, some
post-secondary education among the majority of the sample. In total, 80% of participants in
the GMT group and 93% of participants in the WL group self-reported being prescribed an
anti-depressant at baseline (e.g., SSRI, SNRI, or Tricyclic). See Table 2 for further information
regarding the medication status of participants. The mean BDI-II score at baseline was
29.72 (SD = 11.90) suggesting a level of moderate-to-severe depression in this sample.
The mean BAI at baseline was 24.98 (SD = 14.47) indicating a moderate level of anxiety
in this sample. The mean CAPS-5 score among trauma-exposed individuals was 19.10
(SD = 15.44). Intelligence quotient (IQ) was estimated using the Wechsler Abbreviated

Brain Sci. 2022, 12, 864

8 of 14

Scale of Intelligence, 2nd Edition [47], using one subscale from the verbal comprehension
index (vocabulary) and one perceptual reasoning index (matrix reasoning). The mean IQ
score of the sample was 105.02 (SD = 12.32), indicating average intelligence of the sample.
See Table 2 for participant demographic and clinical characteristics by group.
Table 2. Means and standard deviations for participant demographics and outcome variables for
baseline, post-treatment and three-month follow-up times, with results of multivariate simple effects
of time and pairwise comparison between timepoints.
Variable

Group

Mean (SD)

Age

GMT
WLC
GMT
WLC

52.0 (8.77)
46.64 (11.69)
14.80 (2.01)
15.43 (2.90)

Medication

Group

%

Anti-depressant (e.g., SSRI, SNIR,
Tricyclic)

GMT

80.00

WL
GMT
WL
GMT
WL
GMT
WL
GMT
WL

92.86
20.00
35.71
40.00
28.57
20.00
7.14
13.33
7.14

Group

Time 1
Mean (SD)

Time 2
Mean (SD)

Time 3
Mean (SD)

Pairwise
Comparisons

GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC

23.13 (12.54)
27.00 (16.06)
29.46 (11.33)
30.07 (12.42)
58.43 (13.09)
59.64 (12.86)
52.27 (8.23)
53.79 (12.09)
0.03 (0.72)
0.25 (1.24)
−0.02 (0.62)
0.32 (1.28)
0.27 (1.19)
0.00 (0.76)
−0.20 (0.82)
−0.11 (0.63)
40.93 (7.79)
42.00 (10.96)
40.43 (5.98)
40.07 (8.06)
48.29 (7.55)
46.86 (9.41)
46.32 (9.34)
51.21 (5.77)
10.50 (2.24)
9.86 (3.09)
49.79 (8.35)
47.00 (12.86)
50.29 (10.0)
48.57 (11.69)
67.23 (11.20)
67.71 (9.24)
49.92 (9.89)
47.00 (11.34)
50.61 (7.68)
47.93 (10.28)
49.38 (11.64)
46.71 (10.99)

19,47 (11.96)
27.50 (15.97)
25.60 (13.73)
28.64 (14.28)
51.85 (16.82)
60.79 (11.46)
59.00 (9.50)
56.50 (11.84)
0.53 (0.94)
0.61 (1.11)
0.41 (0.85)
0.43 (1.22)
0.17 (1.04)
−0.11 (0.98)
−0.20 (0.89)
0.14 (0.89)
39.07 (7.41)
43.79 (12.27)
40.43 (8.93)
39.21 (10.05)
52.36 (6.59)
48.50 (7.36)
51.00 (9.69)
51.29 (7.85)
11.07 (2.06)
10.21 (3.31)
52.00 (12.17)
49.50 (12.82)
51.36 (8.22)
52.71 (14.31)
71.38 (11.33)
72.36 (10.76)
51.08 (7.85)
47.93 (8.90)
51.69 (8.46)
48.86 (7.28)
49.69 (7.36)
46.21 (9.36)

21.45 (13.17)
25.71 (14.54)
25.20 (11.90)
31.93 (12.04)
51.12 (13.92)
60.07 (10.77)
57.50 (8.15)
57.21 (11.99)
0.67 (0.81)
0.75 (1.31)
0.38 (0.88)
0.39 (1.36)
0.21 (0.89)
−0.04 (1.18)
−0.21 (0.94)
0.18 (1.19)
38.73 (8.51)
44.29 (12.74)
39.81 (8.76)
40.43 (9.77)
49.84 (6.96)
48.00 (8.77)
50.23 (9.62)
51.65 (4.75)
11.09 (2.39)
10.36 (3.59)
52.63 (13.58)
52.64 (9.38)
52.18 (15.13)
53.29 (13.47)
66.68 (6.14)
72.36 (13.12)
50.30 (11.07)
47.79 (8.95)
51.80 (8.90)
48.64 (9.190
47.90 (12.13)
46.29 (8.41)

↓ T1 to T2 *
n.s.
n.s.
n.s.
↓ T1 to T2 **
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
↑ T1 to T2 *
n.s.
↑ T1 to T2 ***
n.s.
↑ T1 to T2 **
n.s.
n.s.
↑ T1 to T3 *
n.s.
↑ T1 to T3 *
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.

Education

Atypical Antipsychotic
Benzodiazepine
Anti-convulsant
Lithium

Variable
BAI Total Score
BDI Total Score
CFQ Total Score
CVLT Trial 1–5 T-Score
CVLT Short Delay Free Recall Z-Score
CVLT Long Delay Free Recall Z-Score
CVLT Total Repetitions Z-Score
CVLT Total Intrusions Z-Score
Stroop Word T-Score
Stroop Color T-Score
Stroop Interference T-Score
Stroop Color-Word T-Score
WASI Coding Scaled Score
TMT-A T-Score
TMT-B T-Score
WCST Total Correct T-Score
WCST Total Errors T-Score
WCST Perseverative Errors T-Score
WCST Non-Perseverative Errors T-Score
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Table 2. Cont.
Variable
CPT Omission Error T-Score
CPT Commission Errors
CPT Hit Reaction Time T-Score
CPT Variability T-Score
CPT d’ T-Score

Group

Time 1
Mean (SD)

Time 2
Mean (SD)

Time 3
Mean (SD)

Pairwise
Comparisons

GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC
GMT
WLC

57.99 (12.57)
51.97 (12.46)
52.63 (9.44)
53.31 (13.14)
55.10 (11.41)
57.83 (11.80)
54.71 (9.46)
56.59 (15.06)
49.40 (10.06)
51.14 (13.96)

51.42 (14.66)
50.83 (6.95)
45.93 (7.91)
50.84 (12.04)
56.49 (8.63)
55.27 (11.72)
51.24 (11.48)
53.28 (13.11)
46.09 (9.65)
50.03 (10.37)

51.26 (12.38)
54.92 (14.13)
46.11 (6.93)
50.45 (12.63)
53.70 (8.01)
58.20 (12.43)
54.50 (11.53)
52.98 (16.11)
45.89 (9.49)
47.62 (10.72)

n.s.
n.s.
↓ T1 to T2 *
n.s.
n.s.
n.s.
n.s.
n.s.
↑ T1 to T3 *
n.s.

CPT T-Scores are interpreted as higher = worse performance. Partial eta-squared interpreted approximately as
small = 0.01; medium = 0.10 and large = 0.25. Results reported in this table are for the simple main effects, not
the overall ANOVAs. n.s. = No significant differences between any time points. Legend. BAI = Beck Anxiety
Inventory; BDI = Beck Depression Inventory; CFQ = Cognitive Failures Questionnaire; CPT = Conners’ Continuous
Performance Test 2nd Edition; CVLT = California Verbal Learning Test-Second Edition; Stroop = Golden Stroop
Task; TMT = Trail-Making Task-A/B; WASI = Wechsler Adult Scale of Intelligence; WCST = Wisconsin Card
Sorting Test. * Pairwise comparison p < 0.05 ** Pairwise comparison p < 0.01 *** Pairwise comparison p < 0.001 n.s.
Pairwise comparison nonsignificant. ↓ decreased; ↑ increased.

3.1. Neuropsychological Assessment
Means and standard deviations as well as simple main effects results for all variables
are presented in Table 2 for reference, and significant results are detailed below. A set of
independent samples t-tests between variables indicated that there were no significant
baseline differences between the two groups.
3.1.1. Attention/Concentration and Processing Speed
A significant main effect of time (F(1,27) = 3.63, p = 0.040, η2 P = 0.168) was observed for
the CPT-II d’ (an individual’s ability to differentiate targets from non-targets) with pairwise
comparisons revealing that the GMT group improved significantly from time 1 to time 3
(p = 0.042) while the WLC group did not (p > 0.05). There was also a significant main effect
of time for WAIS-IV Coding (F(1,27) = 5.89, p = 0.022, η2 P = 0.185) with pairwise comparisons
revealing that the GMT group improved significantly from pre- to post-treatment (p = 0.044,
η2 P = 0.146) while the WLC group did not (p = 0.368, η2 P = −0.63).
3.1.2. Response Inhibition
A significant main effect of time was also observed for CPT-II commission errors
(F(1,27) = 6.24, p = 0.019, η2 P = 0.189). Pairwise comparisons revealed that the GMT group
improved significantly from pre- to post-treatment (p = 0.014, η2 P = 0.280) while the WLC
group did not (p = 0.535, η2 P = 0.045). There was a significant main effect of time for the
Stroop Color–Word trial (F(1,27) = 5.91, p = 0.022, η2 P = 0.167) as well as a near-significant
interaction effect for the Stroop Interference score (F(1,27) = 4.03, p = 0.054, η2 P = 0.138).
Here, pairwise comparisons showed that the GMT group improved significantly over
treatment for the Color–Word trial (p = 0.018, η2 P = 0.295) and for the Interference score
(p = 0.002, η2 P = 0.436) while the WLC group did not (p = 0.553, η2 P = 0.046 and p = 0.922,
η2 P = 0.006).
3.1.3. Self-Report Questionnaires
There was a near-significant interaction effect for CFQ score (F(1,27) = 4.12, p = 0.052,
η2 P = 0.132), where pairwise comparisons revealed that the GMT group improved significantly from pre- to post-treatment (p = 0.034, η2 P = 0.228) while the WLC group did
not (p = 0.930, η2 P = 0.005). There was also a significant main effect of time (p =0.042,
η2 P = 0.144) for the BAI with pairwise comparisons indicating that the GMT group improved from time 1 to time 2 (p = 0.046) while the WLC group did not (p = 0.353).
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3.1.4. PTSD Severity
Multiple linear regression analyses were conducted with baseline CAPS-5 severity
scores and changes in improved neuropsychological test scores and self-report questionnaires. These analyses were limited to participants in the GMT group that met criterion
A for PTSD diagnosis: exposure to actual or threatened death, serious injury, or sexual
violence (APA, 2013). Baseline symptom severity was negatively correlated with change in
WAIS-IV coding (F(1,8) = 5.42, p = 0.045, β = −0.899), but there was no significant correlation
with change in CPT-II d’(F(1,8) = 1.78, p = 0.231, β = −0.418). Change in response inhibition
was not significantly correlated with baseline symptom severity for CPT-II commission
errors (F(1,8) = 0.436, p = 0.528, β = −0.182), the Stroop Color–Word trial (F(1,8) = 0.09,
p = 0.776, β = −0.048), or the Stroop Interference score (F(1,8) = 0.87, p = 0.378, β = −0.129).
Change in the CFQ was also not significantly correlated with baseline symptom severity
(F(1,8) = 0.206, p = 0.662, β = −0.158).
4. Discussion
The aim of the present study was to conduct an exploratory pilot investigation of
the implementation of GMT in a sample of individuals with MDD, with an additional
objective being to identify variables of interest for future large-scale investigations (i.e.,
those variables that demonstrate improvement in this pilot study). The secondary aim of
the study was to explore how co-morbid PTSD symptom severity among trauma-exposed
individuals with MDD may affect response to treatment. The results of this small pilot
trial point towards focused and specific gains in neurocognitive performance on tasks
related to attention, concentration and response inhibition following GMT administration.
Specifically, improvements were observed for commission errors as well as detectability
(d’) on the CPT-II, WAIS-IV Coding, and the Color–Word and Interference scores from
the Stroop Task, relative to the WLC reference group. Effect sizes ranged from moderate
(η2 P = 0.167) to large (η2 P = 0.436) highlighting a potentially strong treatment effect on
these variables. Finally, there was also a significant improvement in ratings of subjective
cognition in the GMT group. Importantly, all comparisons were significant between the preand post-treatment or pre-treatment and follow-up time points, indicating that these gains
were made either exclusively during treatment or across the entire study window, and
that no significant loss of gains was observed between post-treatment and the three-month
follow-up assessment. Notably, among trauma-exposed individuals, heighted symptoms
of PTSD were associated with diminished improvements on a measure of processing speed
(WAIS-IV Coding), suggesting that co-morbid symptoms of PTSD may reduce response
to treatment on this key index of cognitive performance. It is possible that the cumulative
effects of PTSD and MDD on cognition [6,7] may account for the attenuated effect of
treatment on processing speed. However, it is notable that comorbid PTSD symptoms
did not attenuate the level of improvement on other variables assessed in this study (e.g.,
response inhibition, sustained attention, subjective cognitive difficulties). These findings
are encouraging, suggesting that GMT may be equally effective in ameliorating cognitive
difficulties among individuals with MDD with and without comorbid PTSD.
Critically, improvements in neuropsychological performance were observed on variables associated classically with cognitive impairment in MDD. GMT is designed to hone
skills related to the brain’s sustained attention system, regulated by regions including the
dorsolateral prefrontal cortex, posterior parietal and thalamic regions [24,48]. These regions
may underscore important aspects of cognitive and behavioral therapies by improving
concentration and attention in session, and by improving memory of content learned in
session. Treatments for depression, including both antidepressants and cognitive behavioral therapies, have a positive impact on cognitive symptoms [11], but the pivot of focus
toward cognitive remediation strategies may highlight the opposite end of the two-tailed
hypothesis, that improving cognitive function may act to improve response to treatment.
Indeed, particularly in relatively high-functioning samples, cognitive remediation might
best be applied in MDD as an adjunctive treatment. Accordingly, future investigations
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of GMT may benefit from tailoring to the specific needs of the population (e.g., military
members, public safety personnel and civilians) by incorporating relevant examples and
in-session content. The reduced response to treatment of reductions in processing speed
observed among individuals with more severe symptoms of PTSD also points to potential
benefits for treatment approaches that address both disorders. A phased approach to
treating comorbid MDD and PTSD with psychotherapy, for example, has shown high
effectiveness in reducing symptoms [49].
Visual inspection of means and SDs in Table 2, as well as observations of effect size,
suggest our sample may simply have been underpowered to reach statistical significance in
some cases. Moreover, previous research suggests that improvements in cognitive function
may reduce depressive symptoms [50]. Although not significant in our small sample, visual
inspection of Table 2 reveals BDI-II scores fell from the low-severe range over treatment to
the moderate range at post-treatment; these symptom scores remained relatively constant
among waitlist controls. Further exploration of the impact of GMT on depressive symptoms
is warranted.
The sample, overall, was relatively high functioning. In most cases, normed scores for
both groups tended to be clustered near the average range with the majority of T-Scores
falling between 45 and 55, and most of the improvements observed here moved scores
from the low average to average range, or simply remained in the average range. Overall,
however, this sample did not present with pronounced cognitive deficits beyond the low
average range. Some variables, such as the WCST total correct, may have been impacted
by ceiling effects. These observations underscore the importance of the large gains in
subjective cognition observed here, particularly given that a nine-week program might
not be of sufficient length or intensity to yield improvement in performance in cognitive
domains that are very subtly impaired. In general, in disorders such as MDD and PTSD,
where cognitive effects may be subtle (i.e., in the low average or mildly impaired range), it
is critical that neuropsychological tests be of sufficient difficulty to capture subtle cognitive
impairments, and not fall prey to ceiling effects.
Limitations from this pilot study can be used to inform future investigations. As stated,
this sample may have lacked sufficient power to detect subtle performance deficits or small
gains in performance. This is a common limitation of pilot investigations. Moreover, there
is potential for Type I error in this study given the large number of comparisons performed,
but this was deemed acceptable given the exploratory nature of the study. Additionally,
we were unable to control for the effects of participation in other treatments for MDD (e.g.,
psychotherapy, medication); thus it is possible that improvements reported in this study
may have been associated with participation in other treatments. However, this is unlikely
as, as noted above, cognitive impairment has been reported to remain following remission
of MDD [8]. There were a significant number of dropouts in this study. However, the
majority of dropouts occurred prior to participation in GMT (e.g., after screening, but before
initial testing, or after initial testing, but before the GMT group). One individual dropped
out after the first GMT session. Although the reasons for drop-out was not recorded, it is
possible that individuals dropped out due to the burden of participating in the assessment
or the need to commit to a 9-week group treatment. Future studies may mitigate the impact
of testing by selecting fewer measures based on previous findings, focused on core cognitive
domains that are expected to improve following GMT. Notably, the dropout rate in our
study is consistent with high dropout rates found across psychological interventions for
depression [51], where it is possible that the symptoms of depression (e.g., anhedonia, low
motivation) may interfere with initiation or completion of treatment. A major limitation
of the study is that it did not explore the interaction of cognition and emotion through
assessment of emotional regulation among individuals with MDD and the use of cognitive
tasks that may be perturbed by emotion (e.g., the emotional Stroop). Strengths of the study
included good completion of both post-treatment and three-month follow-up assessments,
with relatively low missing data overall.
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5. Conclusions
On balance, the results of this pilot study, although tempered by the small sample
size and other limitations discussed above, are in line with previous investigations of GMT
in various clinical populations in that we observed focused gains in some standardized
variables, as well as improvements in subjective cognition. The burgeoning focus on
non-traditional facets of MDD symptom presentation, such as alterations in cognitive performance (an important but often overlooked moderator of functional outcomes) represents
a vital shift toward remediation of factors that may diminish response to pharmacological
and non-pharmacological treatment. Improvements in cognitive performance would be
expected to have downstream impacts on work and psychosocial functioning. Critically,
treatment gains were observed primarily in cognitive subdomains that are affected in
depressed samples and are targeted for improvement by GMT; thus revealing encouraging specificity of this intervention to individuals with MDD. PTSD symptoms, which are
frequently comorbid in MDD [3], were associated with reduced response to treatment of
alterations in processing speed, suggesting strongly the need to study further the impact of
PTSD and trauma exposure on cognitive functioning in MDD and in treatment response.
Subsequent studies of the use of GMT in neuropsychiatric conditions should include larger
samples and an active control group to determine the specific effects of GMT relative to
other treatment options.
Author Contributions: Conceptualization, M.C.M. and J.E.B.; formal analysis, B.D.S. and D.H.C.;
investigation, J.E.B.; writing—original draft preparation, J.E.B., D.H.C. and B.D.S.; writing—review
and editing, A.P., R.E.M. and M.C.M.; supervision, M.C.M.; project administration, J.E.B. and C.O.;
funding acquisition, R.A.L. and M.C.M. All authors have read and agreed to the published version of
the manuscript.
Funding: This work was supported by a grant from the J.P. Bickell Foundation awarded to M.C.M.
J.E.B. was supported by a Doctoral Studentship Award from the Research Institute at St. Joe’s
Hamilton. D.H.C. was supported by a Post-Doctoral Fellowship Award from The Research Institute
at St. Joe’s Hamilton. M.C.M. is supported by the Homewood Chair in Mental Health and Trauma
at McMaster University. R.A.L. is supported by the Harris-Woodman Chair in Psyche and Soma at
Western University of Canada.
Institutional Review Board Statement: Ethics approval was granted by the institution’s review
board, the Hamilton Integrated Research Ethics Board (reference number: 2015-0416-GRA).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: Transfer of data outside the housing institution is currently not supported by the institution’s ethics policy.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.
4.
5.
6.
7.

Kessler, R.C.; Petukhova, M.; Sampson, N.A.; Zaslavsky, A.M.; Wittchen, H.U. Twelve-month and lifetime prevalence and lifetime
morbid risk of anxiety and mood disorders in the United States. Int. J. Methods Psychiatr. Res. 2012, 21, 169–184. [CrossRef]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5; American Psychiatric Association:
Arlington, VA, USA, 2022. [CrossRef]
Angelakis, S.; Nixon, R. The Comorbidity of PTSD and MDD: Implications for Clinical Practice and Future Research. Behav.
Change 2015, 32, 1–25. [CrossRef]
Afifi, T.O.; MacMillan, H.L.; Boyle, M.; Taillieu, T.; Cheung, K.; Sareen, J. Child abuse and mental disorders in Canada. Can. Med.
Assoc. J. 2014, 186, 324–332. [CrossRef] [PubMed]
Shih, R.A.; Schell, T.L.; Hambarsoomian, K.; Marshall, G.N.; Belzberg, H. Prevalence of PTSD and Major Depression following
trauma-center hospitalization. J. Trauma 2010, 69, 1560–1566. [PubMed]
Rock, P.L.; Roiser, J.P.; Riedel, W.J.; Blackwell, A.D. Cognitive impairment in depression: A systematic review and meta-analysis.
Psychol. Med. 2014, 44, 2029–2040. [CrossRef]
Scott, J.C.; Matt, G.; Wrocklage, K.M.; Crnich, C.; Jordan, J.; Southwick, S.M.; Krystal, J.H.; Schweinsburg, B.C. A quantitative
meta-analysis of neurocognitive functioning in posttraumatic stress disorder. Psychol. Bull. 2015, 141, 105–140. [CrossRef]

Brain Sci. 2022, 12, 864

8.
9.
10.

11.
12.
13.
14.
15.
16.
17.
18.

19.
20.
21.
22.
23.

24.

25.

26.
27.
28.

29.

30.
31.
32.

13 of 14

Bora, E.; Harrison, B.J.; Yücel, M.; Pantelis, C. Cognitive impairment in euthymic major depressive disorder: A meta-analysis.
Psychol. Med. 2013, 43, 2017–2026. [CrossRef]
Larsen, S.E.; Fleming, C.J.E.; Resick, P.A. Residual symptoms following empirically supported treatment for PTSD. Psychol.
Trauma Theory Res. Pract. Policy 2019, 11, 207–215. [CrossRef]
Parlar, M.; Frewen, P.A.; Oremus, C.; Lanius, R.A.; McKinnon, M.C. Dissociative symptoms are associated with reduced
neuropsychological performance in patients with recurrent depression and a history of trauma exposure. Eur. J. Psychotraumatol.
2016, 7, 29061. [CrossRef]
Lam, R.W.; Kennedy, S.H.; McIntyre, R.S.; Khullar, A. Cognitive dysfunction in major depressive disorder: Effects on psychosocial
functioning and implications for treatment. Can. J. Psychiatry 2014, 59, 649–654. [CrossRef]
Yen, Y.C.; Rebok, G.W.; Gallo, J.J.; Jones, R.N.; Tennstedt, S.L. Depressive symptoms impair everyday problem-solving ability
through cognitive abilities in late life. Am. J. Ger. Psychiatry 2011, 19, 142–150. [CrossRef]
McLennan, S.N.; Mathias, J.L. The depression-executive dysfunction (DED) syndrome and response to antidepressants: A
meta-analytic review. Int. J. Ger. Psychiatry 2010, 25, 933–944. [CrossRef] [PubMed]
Crews, W.D.; Harrison, D.W. The neuropsychology of depression and its implications for cognitive therapy. Neuropsychol. Rev.
1995, 5, 81–123. [CrossRef] [PubMed]
Nijdam, M.J.; Gersons, B.P.; Olff, M. Response to psychotherapy for posttraumatic stress disorder: The role of pretreatment verbal
memory performance. J. Clin. Psychiatry 2015, 76, e1023–e1028. [CrossRef] [PubMed]
Motter, J.N.; Pimontel, M.A.; Rindskopf, D.; Devanand, D.P.; Doraiswamy, P.M.; Sneed, J.R. Computerized cognitive training and
functional recovery in major depressive disorder: A meta-analysis. J. Affect. Dis. 2016, 189, 184–191. [CrossRef]
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